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Retroviral proteases (PRs) have a unique specificity that allows cleavage of sites with or without a P1′ proline.
A P1′ proline is required at the MA/CA cleavage site due to its role in a post-cleavage conformational change
in the capsid protein. However, the HIV-1 PR prefers to have large hydrophobic amino acids flanking the
scissile bond, suggesting that PR recognizes two different classes of substrate sequences. We analyzed the
cleavage rate of over 150 combinations of six different HIV-1 cleavage sites to explore rate determinants of
cleavage. We found that cleavage rates are strongly influenced by the two amino acids flanking the amino
acids at the scissile bond (P2–P1/P1′–P2′), with two complementary sets of rules. When P1′ is proline, the P2
side chain interacts with a polar region in the S2 subsite of the PR, while the P2′ amino acid interacts with a
hydrophobic region of the S2′ subsite. When P1′ is not proline, the orientations of the P2 and P2′ side chains
with respect to the scissile bond are reversed; P2 residues interact with a hydrophobic face of the S2 subsite,
while the P2′ amino acid usually engages hydrophilic amino acids in the S2′ subsite. These results reveal that
the HIV-1 PR has evolved bi-functional S2 and S2′ subsites to accommodate the steric effects imposed by a
P1′ proline on the orientation of P2 and P2′ substrate side chains. These results also suggest a new strategy
for inhibitor design to engage the multiple specificities in these subsites.Introduction
The human immunodeficiency virus type 1 (HIV-1) 
protease (PR), encoded in the viral pro gene, utilizes 
two aspartic acid side chains coordinating a water 
molecule to hydrolyze a peptide bond. Each subunit 
of the homodimeric PR contributes one aspartic acid 
to create this active site [1–3]. Surrounding these 
aspartates is a channel within the enzyme where a 
7- to 8-amino-acid stretch of protein interacts with 
the PR to determine its suitability for cleavage, 
with these interactions occurring through a series 
of subsites within the protease along this channel 
[4–6]. The PR itself is initially embedded in the viralGag-Pro-Pol precursor [7]. Upon dimerization of
monomeric subunits embedded within a pair of
precursor polyproteins, the enzyme gains function-
ality and completes a three- or four-step intramolec-
ular processing sequence to free its amino-terminal
ends [8–10]. The resulting increase in structural
stability enables the PR to intermolecularly cleave
the primary HIV-1 structural polyprotein, Gag, as well
as free the reverse transcriptase (RT) and integrase
(IN) enzymes from the residual intermediates of
Gag-Pro-Pol [11,12]. Cleavage of the five processing
sites within Gag releases small mature virion proteins,
matrix (MA), capsid (CA), spacer peptide 1 (SP1),
nucleocapsid (NC), spacer peptide 2 (SP2), and p6,
and the cleavage proceeds in a specific order [12–16].
Protein processing results in the maturation of the
genomic RNA dimer [17], assembly of the pre-reverse
transcription complex, and envelopment of the ribonu-
cleoprotein core within a capsid cone [18]. Incomplete
processing results in a non-infectious virus particle
[19–22].
Each of the ten cleavage sites recognized by the
HIV-1 PR within Gag and Gag-Pro-Pol has a unique
amino acid sequence (Table 1). There are a few
common features, for example, a β-branched amino
acid cannot occupy the P1 position [16,23], the
amino acids directly flanking the scissile bond
(P1/P1′) favor hydrophobic amino acids [24], and the
sequences occupy a conserved shape or substrate
envelope [25,26], which is maintained even after
substrate and enzyme co-evolution in response
to PR inhibitors [27–30]. Nevertheless, no clear
patterns exist to explain the varied rates at which
they are cleaved [31]. Addressing that question is
complicated by the fact that suboptimal cleavage site
sequences could be used to help in the sequential
cleavage pathway, or conformational and/or post-
cleavage functional determinants could limit the use
of optimal amino acids at the cleavage sites [32–34].
An unusual feature of the retroviral protease family is
the ability to cleave sites with or without a proline
in the P1′ position [16], that is, just downstream of
the scissile bond (MEROPS https://www.ebi.ac.uk/
merops/cgi-bin/peptidase_specificity). The ability
to cleave next to a proline is necessitated by the
requirement for a N-terminal proline in the mature CA
protein that forms an intramolecular salt bridge to
stabilize the post-cleavage CA structure and enable
formation of the mature CA lattice [35–40]. Thus, this
cleavage event is part of the regulation of virion
assembly. This has previously led us to suggest that
PR cleavage sites fall into two classes, those with a
proline at P1′ and those with a hydrophobic amino
acid at P1′ [24]. Left unclear is whether determinants
of substrate specificity differ between the groups, and
if so, how the homodimeric PR achieves multiple
specificities.
Here we report an extensive mutational analysis
of six different HIV-1 PR cleavage sites using aTable 1. Amino acid sequences of HIV-1 cleavage sites
Site Abbreviation P4
Matrix/capsid MA/CA S
Capsid/spacer peptide 1 CA/SP1 A
Spacer peptide 1/nucleocapsid SP1/NC A
Nucleocapsid/spacer peptide 2 NC/SP2 R
Spacer peptide 2/p6 SP2/p6 P
Transframe (internal)/transframe TF*/TF D
Transframe/protease TF/PR S
Protease/reverse transcriptase PR/RT T
Reverse transcriptase/RNase H RT/RTH A
RNase H/integrase RTH/IN Rpreviously developed two-substrate protease reac-
tion to compare relative rates of cleavage [31]. In
total, 152 substrates were evaluated to define how
sequence influences cleavage rate among the sites.
We discovered that the PR binds the two classes of
cleavage sites, as defined by the P1′ amino acid, in
two different ways. The orientations of the P2 and
the P2′ amino acid side chains within the S2 and
S2′ subsites differ depending on whether or not
a proline occupies P1′. This directional difference
determines whether the subsites preferentially ac-
commodate a hydrophobic or hydrophilic residue,
an interpretation consistent with our previous struc-
tural analysis of substrates bound to a catalytically
inactive PR [25,26,41]. The MA/CA and SP1/NC
cleavage sites appear to be optimized for cleavage
rate for the two classes of cleavage sites, while other
sites represent suboptimal examples of these two
classes of cleavage sites whose rates can be
increased by manipulation of the P2 or P2′ amino
acid. Thus, the HIV-1 PR has evolved bi-functional
S2 and S2′ subsites to accommodate changes in
side chain orientation in the P2 and P2′ substrate
side chains imposed by the requirement to have a
subset of cleavage sites with a P1′ proline.Results
Two-substrate proteolysis allows accurate
cross-reaction comparisons
For investigation of HIV-1 PR sequence specificity,
we developed a system to compare the processing
rate of cleavage sites under near-physiological
conditions and independent of context. Efficient
cleavage near neutral pH requires a globular
substrate [31]. Six of the 10 HIV-1 PR cleavage
sites were investigated in this study. Briefly, the full
MA/CA region of Gag served as an internal control
in the two-substrate proteolysis system. A modified
substrate (GMCΔ) was made from MA/CA by adding
glutathione S-transferase at the N-terminus of MA
and truncating the C-terminal domain of CA toP3 P2 P1 P1′ P2′ P3′ P4′
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introduce size differences between the substrates
and the cleaved products after proteolysis. A binding
site for the Lumio Green Reagent (Invitrogen) was
introduced into the Cyclophilin A loop of CA within
both proteins, MA/CA and GMCΔ, to improve the
detection of low-abundance cleavage products
[42,43]. Processing of the MA/CA cleavage site within
GMCΔ was as efficient as the processing of the MA/
CA cleavage site within MA/CA, indicating that the
alterations made to GMCΔ do not affect the rate of
cleavage of the MA/CA site (Supplementary Fig. 1a).
Five other HIV-1 cleavage sites [shown as bold in
Table 1; CA/SP1, SP1/NC, SP2/p6, TF/PR (TF:
Transframe), andRTH/IN (RTH: reverse transcriptase
andRNaseH, IN: Integrase]) were placed into theP4–
P4′ positions of the cleavage site between theMAand
CA doma ins o f GMCΔ , each rep lac ing
the homologous MA/CA cleavage site.
Although context was constant between all of the
transplanted sites, we further minimized the influ-
ence of context by flanking the P4-P4′ residues
with three glycines on each side (GMCΔgly). This
caused a modest and uniform 3-fold decrease in the
cleavage rate for all sites except for TF/PR which
exhibited a 15-fold decline, suggesting a greater
interaction with amino acids beyond P4 and/or
P4′ for this site (Supplementary Fig. 2). The control
MA/CA substrate was likewise modified to include
glycine spacer regions flanking the cleavage sites
(MA/CA-gly). In this system, we use the initial rate
of cleavage to compare the specificity constants
(kcat/Km) between the two substrates, which can
be done directly when the substrates are at equal
concentration when the reaction is initiated. We
previously utilized this system to determine the
relative processing rates of the wild-type cleavage
sites from the Gag and Gag-Pro-Pol polyproteins
[31]. However, these conditions do not recapitulate
the high protein and substrate concentrations that
are present in the virion.
Only 11% of substrates in the library improved
processing more than 3-fold
In total, 146 mutant HIV-1 cleavage sites were
tested based on the six wild-type sites (Fig. 1a,
Supplementary Table 1). Most mutant sites differed
from their wild-type parent by a single amino acid
substitution, although 14 were dual substitutions;
the substitutions chosen for each site were designed
using the diversity of other sites as a guide. With
the exception of the SP2/p6 and TF/PR cleavage
sites, whose wild-type sequences were inefficiently
cleaved, we also tested an alanine substitution in
each position. Each site had every position mutated
at least once, and 43 of 48 positions were tested with
at least two different substitutions.
The most common outcome of these mutated sites
(65/146) was a cleavage rate change within 3-foldof their respective wild-type sequence (Fig. 1b).
We have largely limited the analysis of rate changes
to those greater than 3-fold to focus on the larger
effects, although under most circumstances the
assay was accurate in measuring changes below
this level of difference. Of the remaining 81
mutations, 28 slowed the rate of cleavage by 3- to
10-fold, and 26 by greater than 10-fold. Only 16 of
the mutant sites tested improved the rate of cleavage
over the parent site; those conferring a 10-fold or
greater increase occurred only with substitutions
within the inner four positions of the cleavage site
(P2–P2′).
A small fraction of mutant substrates (11/146)
had undetectable levels of cleavage, even when
examined in an extended assay. Like the mutations
that had the greatest positive impact on cleavage
rate, these mutations were mostly within the central
amino acid positions P2–P2′. Outside of this inner
region, only mutations at the P3 position also ablated
cleavage. However, these P3 cleavage-negative
mutations were in the background of the SP2/p6
and TF/PR cleavage sites where the slow initial rate
of processing for these two sites limited our ability to
detect decreases in their efficiencies of cleavage
beyond 20-fold. Further inspection of the patterns of
changes in rates among the different cleavage sites
ultimately revealed common features, as described
in the next section.
A working model for HIV-1 protease specificity
Interpretation of the results below will reference
a working model that emerged while analyzing the
data. The model suggests the existence of two
prototypic sequence motifs: NΩ/PI (Asn, mainly Phe
or Tyr/Pro, Ile) and βΦ/ΦE (β-branched aliphatic,
hydrophobic/hydrophobic, Glu). When optimized for
cleavage rate, both motifs form critical hydrogen
bonds with residues 29 and 30 of one of the PR
subunits. In the βΦ/ΦE motif, the P2′ glutamic acid
(or glutamine) forms these hydrophilic interactions
in the S2′ subsite; the P1′ proline in an NΩ/PI
site shifts this interaction to the P2 asparagine in the
S2 subsite. The reciprocal P2/P2′ residues are
not involved in forming hydrogen bonds, but rather
are β-branched amino acids, commonly isoleucine
or valine, and they participate in distinct hydropho-
bic interactions with PR residues within the same
S2/S2′ subsites. The data presented below show
that the MA/CA and the SP1/NC sites are largely
optimal for cleavage rate for the NΩ/PI and βΦ/ΦE
sites, respectively, and that the remaining four
sites can be manipulated to increase or decrease
the rate of cleavage based on similarity to one
or the other motif. One variation on this theme is
that the size of the P1′ amino acid in the βΦ/ΦE













































































































































































































































































































































































































































































































































Improve by 3- to 10-fold
+/- 3-fold
Worsen by 3- to 10-fold 
Worsen by >10-fold
Cleavage undetected
Total Count = 145
Fig. 1. Relative processing efficiency of the altered substrates. (a) Distribution of GMCΔgly substrate cleavage
efficiencies relative to the MA/CA-gly internal control substrate. The relative rates of substrate sites with wild-type HIV-1
Gag sequences are indicated with arrows colored according to the figure insert. The dashed gray line represents the lower
limit of detection in an extended 2-h proteolysis assay. All bars extending below this line indicate substrates for which we
did not observe cleavage. Site sequences and precise rate values are located in Supplementary Table 1. (b) Distribution of
mutant substrate cleavage rates relative to their respective wild-type site.MA/CA (SQNY/PIVQ)—optimized for cleavage
rate given a P1′ proline
MA/CA typifies the NΩ/PI motif due to its distinc-
tive requirement for a P1′ proline in a post-cleavage
conformation change. Proline as a constrained
amino acid is a challenging substrate for most
proteases such that no other proteases are known
with mixed substrate specificity that includes a P1′
proline (MEROPS https://www.ebi.ac.uk/merops/
cgi-bin/peptidase_specificity). Despite the presence
of a P1′ proline in the MA/CA site, this site is cleaved
relatively efficiently by the HIV-1 PR (Fig. 1a),
at about one-tenth the rate of cleavage of the
most rapidly cleaved substrate. Furthermore, no
single mutation within the key P2–P2′ inner regionsignificantly improved the cleavage rate, not even
substitution of the proline (Fig. 2a). These data
support the argument that the amino acid composi-
tion of the MA/CA site is essentially optimized given
a P1′ proline.
While no P2–P2′ substitutions significantly en-
hanced the rate of MA/CA cleavage, several were
deleterious. β-Branched amino acids in P2 had
strongly negative effects despite their frequent
appearance at P2 in other sites, supporting a link
between a P2 asparagine and the P1′ proline.
Structural studies of a MA/CA peptide bound to PR
(PDB: 1KJ4 [25]) showed that the P2 asparagine
side chain extends in the N-terminal direction
(relative to the substrate) to make a hydrogen bond
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Fig. 2. The MA/CA site represents the prototypical NΩ/PI
site. (a) Relative change in processing efficiency for each
mutant of the MA/CA site. Bold text denotes the wild-type
residue at the indicated position. Amino acids within the
grayed region exhibited ±3-fold changes in cleavage rate.
Amino acids located within the regions bordered by dotted
lines exhibited between 3- and 10-fold changes in cleavage
rate. Single amino acid substitutions with equivalent rates are
separated by commas. Dual substitutions of adjacent
residues are represented located halfway between columns
and separated by a “/.” The dashed gray line represents the
lower limit of detection for processingat this site. Positioningof
the P2 amino acid in the S2 subsite (b) and P2′ amino acid in
the S2′ subsite (c). Amino acids from theHIV-1 PRare shown
in yellow and labeled with their single-letter code and residue
number in the PR. Primed versus unprimed residue numbers
denote different PRsubunits. Residues from the substrate are
in green and labeled by three-letter code and positioning
relative to the scissile bond. For both, nitrogenatomsare blue,
oxygen atoms are red, and dashed lines denote hydrogen
bonds. PDB file: 1KJ4.Asp29 and Asp30 (Fig. 2b), an interaction that would
not occur with a hydrophobic P2 amino acid. A P1
phenylalanine or tyrosine was more active than a
P1 methionine or leucine (Fig. 2a), as previously
reported [16,24,44], suggesting that optimal cleav-
age of P1′ proline sites requires a large aromatic
amino acid in P1. In contrast to P2, an asparagine in
P2′ was highly unfavorable (Fig. 2a). The wild-type
amino acid in P2′, isoleucine, yielded the most
rapidly cleaved site, although glutamine or glutamic
acid was well tolerated. Figure 2c shows that the P2′
isoleucine angles away from Asp29′ and Asp30′
in the S2′ subsite, instead forming van der Waals
contacts with the hydrophobic amino acid Ile84′.
Taken together, the data point to a P1′ proline having
an optimal cleavage rate with the motif NΩ/PI.
Most substitutions beyond P2–P2′ caused minimal
changes in the rate of cleavage. However, one
substitution, P4 serine to alanine, did havea significant
negative effect, consistent with previous reports using
peptide substrates [44–46]. The positive effect of this
serine likely results from the ability of the P4 serine
to form a hydrogen bond with the P2 asparagine
when the side chain is oriented away from the scissile
bond. Indeed, putting a P4 serine with P2 asparagine
in a non-P1′ proline site had no effect on cleavage rate
(see below, SP2/p6).
SP1/NC (ATIM/MQRG)—optimized for cleavage
rate
Among the 10 HIV-1 cleavage sites, SP1/NC is the
most rapidly cleaved in its natural context [13–15]
and could conceivably represent an optimal cleav-
age site sequence for the enzyme. Consistent with
this possibility, our prior mutational analysis failed
to significantly improve the rate of cleavage [16],
and none of the 28 substitutions examined here did
either. Among the other sites tested, only a mutated
version of the RTH/IN site was cleaved faster than
the wild-type SP1/NC sequence (Fig. 1a) but at a
rate that was only marginally better (1.2-fold).
Within the P2–P2′ core of SP1/NC (Fig. 3a),
substitution of P2 isoleucine with asparagine signif-
icantly reduced the rate of cleavage, demonstrating
that the sequence requirements for the SP1/NC
and NΩ/PI sites are distinct. This conclusion was
reinforced by the β-branched valine substitution
being well tolerated at the P2 position. Glutamine
and glutamic acid gave equivalent rates as P2′
occupants, whereas small or β-branched alterna-
tives resulted in varying degrees of reduced rates of
cleavage, suggesting that the non-NΩ/PI motif is
based on a β_/_(E/Q) framework. Any of the common
scissile bond residues (i.e., phenylalanine, methio-
nine, and leucine) were active in either P1 or P1′, in
agreement with previously published data [16]. The
non-NΩ/PI motif therefore consists of βΦ/Φ(E/Q),



















































Fig. 3. The SP1/NC site exemplifies an optimized βΦ/ΦE
site. (a) Relative change in cleavage rate for each mutant of
the SP1/NC site. All formatting is consistent with Fig. 2, with
the addition of a non-adjacent dual substitution mutant.
These paired amino acids are boxed and connected by a
solid line. Positioning of the SP1/NCP2 amino acid in the S2
subsite (b) andP2′ amino acid in theS2′ subsite (c). Coloring
is the same as in Fig. 2b and c. PDB file: 1KJ7.E/Q interchangeability was later resolved to favor
glutamic acid, given its higher level of activity in the
presence of a small P1′ residue (see the discussion
of the CA/SP1 site below), yielding the βΦ/ΦE motif.
Analysis of the structure of this substrate bound to
the PR (PDB: 1KJ7 [25]) shows that the side chain
of the P2 isoleucine in the βΦ/ΦE motif interacts
with a hydrophobic pocket formed by Ile50 and Ile84
(Fig. 3b). Meanwhile, the P2′ glutamine forms a
hydrogen bond with the peptide backbone near
Asp30′ of the PR (Fig. 3b), and the amino-groupside chain of the P2′ glutamine may additionally
interact with the side chain of Asp30′ in this context;
furthermore, the P2′ glutamine is oriented toward the
C terminus relative to the substrate, pointing away
from the scissile bond. In comparing the P2 and
P2′ side chains in the two substrate-bound struc-
tures, their orientations are essentially reversed. This
suggests that the S2 and S2′ subsites have two
recognition specificities and are therefore bi-specific.
External to the P2–P2′ region, the most extreme
effect observed was a 9-fold rate loss caused by an
alanine to arginine substitution at P4. Although this
again could suggest P4 as a potential rate-defining
position, other P4 substitutions did not significantly
affect the rate of cleavage of the SP1/NC site,
implying that arginine was the exception, not the
rule. Moreover, arginine and alanine had only small
effects in all other βΦ/ΦE sites.
CA/SP1 (ARVL/AEAM)—a βΦ/ΦE motif site with
a small P1′ residue
The wild-type CA/SP1 sequence contains a
β-branched P2 amino acid and a glutamic acid at
P2′ identifying it as a βΦ/ΦE motif site, in addition to
the absence of a P1′ proline. Accordingly, substitution
of P2 to asparagine had a strongly deleterious effect
(105-fold rate decrease), while isoleucine substituted
for valine had a negligible effect. Moreover, all of
the large common P1 amino acids were equivalently
active substrates for the PR (Fig. 4a). However, in
contrast to SP1/NC where glutamic acid and gluta-
mine were largely equivalent, the P2′ glutamic acid
provided a substrate cleaved 60-fold faster than when
P2′ was glutamine. The CA/SP1 core differs most
significantly from the SP1/NC site at the P1′ position,
with alanine being the smallest hydrophobic/aliphatic
amino acid. Examination of the entire data set
revealed a common preference in P2′ for glutamic
acid over glutamine whenever P1′ was smaller than
phenylalanine. This suggests that P2′ functions as
a key compensatory position to improve PR recogni-
tion when the S1′ subsite is not fully occupied. An
analysis of the crystal structure of this substrate bound
to PR (PDB: 1F7A [25,41]) (Fig. 4b) shows that both
the P2 and P2′ amino acid side chains are oriented
similar to those of the SP1/NC site, consistent with the
βΦ/ΦE motif.
The external amino acids in CA/SP1 (i.e., P4, P3,
P3′, and P4′) were all highly tolerant to substitution
(Fig. 4a). Among changes in size, hydrophobicity,
or conformation of the R-group, only 2 of 11 substitu-
tions changed the rate by greater than 3-fold and none
exceeded a 7-fold change in rate. These results are
consistent with previously published data [47] and
support the idea that substitutions in these distal
positions that elicit significant effects on processing
rate are specific to this cleavage site and not deter-









































































































Fig. 4. Suboptimal βΦ/ΦE sites demonstrate the compensatory role of P2′. The relative change in cleavage rate (a),
positioning of the P2 amino acid (b), and positioning of the P2′ amino acid of the wild-type CA/SP1 cleavage site (c). The
RTH/IN site is represented in panels d, e, and f. Formatting and coloring of the figures remains the same as in Figs. 2 and 3.
PDB files: 1F7A (b, c) and 1KJH (e, f).RTH/IN (RKVL/FLDG)—a βΦ/ΦE motif site with a
large P1′ residue
With the absence of a P1′ proline and the
β-branched valine in P2, the RTH/IN cleavage site
belongs in the βΦ/ΦE motif. Mutagenesis confirmed
this assignment; isoleucine and valine were equiv-
alent in P2, while an asparagine substitution gave
a poor substrate (Fig. 4d). Furthermore, P1 accom-
modated large non-β-branched hydrophobic amino
acids without affecting processing efficiency. An
unusual feature in RTH/IN is the P2′ leucine; all P2′aliphatic amino acids tested were moderately more
active as substrates than glutamic acid. Comparison
of the SP1/NC (Fig. 3c) and RTH/IN structures
(Fig. 4f, PDB: 1KJH REF: [25]) shows similarity
in positioning of both P2′ R-groups, although the
terminal branched carbons of the leucine avoid
positioning that would allow H-bond contacts with
the Asp29′/Asp30′ backbone in favor of hydrophobic
contacts seen in NΩ/PI sites. This ability to substitute
these contacts was unique to the RTH/IN site, as a P2′
leucine in the SP1/NC context reduced cleavage
efficiency nearly 80-fold. The large aromatic P1′ amino
acid in the RTH/IN site could change the side chain
angle of the P2′ amino acid to be more intermediate
between the extremes of the two motifs allowing both
conformations to be sampled for the P2′ side chain.
Alternatively, an inverse relationship exists between
the size of the P1′ amino acid and the importance
of the P2′ position—the smaller the residue in P1′, the
more important the identity of the P2′ position and
therefore which contacts are made in the S2′ subsite.
The non-core amino acids hadmeasureable effects
on the RTH/IN site. The P4 and P3 residues are
both positively charged, and while individual substi-





















































Fig. 5. Hybrid cleavage sites have the lowest inherent ra
positioning of the P2 amino acid (b), and positioning of the P2
structural data were available for the TF/PR site, so it was mo
figures remain the same as in Figs. 2 and 3. PDB files: 1KJFco-substitution increasedRTH/IN processing by 7-fold
(Fig. 4d). In the bound structure, the P4 arginine
occupies the S3 subsite and the P3 lysine occupies
the S4 subsite [25]. This subsite swapping may be
required to accommodate the size of the P4 arginine
at the expense of reduced binding to PR. Conversely,
five of the six substitutions of P3′ and P4′ tested
slowed processing by at least 3-fold, with two of these
substitutions having a greater than 10-fold effect.
Taken together, the cleavage rate of the RTH/IN
site appears subject to influences outside of the




















































te of cleavage. The relative change in cleavage rate (a),
′ amino acid of the wild-type SP2/p6 cleavage site (c). No
deled in panels d, e, and f. Formatting and coloring of the
(b, c) and 1KJ4 (e, f; enzyme only).
SP2/p6 (PGNF/LQSR)—a βΦ/ΦEmotif site despite
a hybrid amino acid sequence
The absence of a P1′ Pro suggests that SP2/p6
should be a βΦ/ΦE motif site, but the asparagine at
P2 is inconsistent with this designation. Isoleucine
in P2 improved processing by 17-fold, while it had a
minimally negative effect in P2′, behavior consistent
with βΦ/ΦE motif sites (Fig. 5a). That a P1′ proline
measurably reduced processing of SP2/p6 com-
pared to leucine or phenylalanine further supports
the motif designation. Structural analysis of the side
chain of the P2 asparagine in SP2/p6 shows its
orientation mimics that of beta-branched amino
acids in P2 when the P1′ amino acid is not proline
(Fig. 5b). This suggests that the nature of the P1′
amino acid determines the orientation of the P2
amino acid, in the case of SP2/p6 placing a polar
asparagine into the hydrophobic face of the S2
subsite with the result being a suboptimal cleavage
rate. In addition, glutamic acid in P2′ enhanced
processing, a finding consistent with an increased
selectivity in P2′ when P1′ is non-aromatic.
Among the distal sites, mutation of the P3 position
with a large polar amino acid significantly affected
SP2/p6 processing. Substituting arginine or gluta-
mine into the P3 position resulted in SP2/p6 sites
that were not detectably cleaved. The P4 proline
creates a distinct conformation in which the P4 amino
acid occupies the S3 subsite with the P3 glycine too
small to fill the S4 subsite [25], and this is likely the
reason for the added selectivity of P3. Consistent
with this, replacing the P4 proline with serine rescues
an otherwise deleterious P3 glutamine substitution
(Fig. 5a).
TF/PR (SFSF/PQIT)—an NΩ/PI motif site with
several suboptimal amino acids
Like MA/CA, the TF/PR site contains a required
P1′ proline, necessary in this case to restrict the
set of cleavage sites available to the Gag-Pro-Pol-
embedded PR [12] and placing this site into the NΩ/
PI motif grouping. In agreement with this designation,
substituting an asparagine into P2 improved process-
ing efficiency 9-fold, and a β-branched amino acid in
P2′ conferred a 25-fold improvement over glutamine
(Fig. 5d). However, replacing the P1′ proline with
phenylalanine or leucine improved the rate of cleav-
age by 24- and 57-fold, respectively. This is in contrast
with the NΩ/PI site at MA/CA, in which substitution of
the proline had minimal effect. This difference likely
results from the absence of any other NΩ/PI-defining
residues flanking the P1′ proline, effectively allowing
the site to function as a βΦ/ΦE motif site when the
proline is removed.
TF/PR resembled themajority of cleavage siteswith
regard to its flanking P4, P3, P3′, and P4′ amino acids.
These outer positions contributed only modestly todetermining the rate of cleavage. The sole outlier—P3
phenylalanine to lysine—resulted in undetectable
levels of cleavage. This mutation could be rescued
in part by a secondary substitution at P2, suggesting
that the observed effect was specific to the TF/PR site
since arginine and lysine are often accommodated
in this position. We additionally note that this, like the
SP2/p6 P3 substitutions that blocked cleavage,
occurred in the substrates with the slowest rate of
cleavage. It may be that slow sites are proportionally
more sensitive to mutations in their outer amino acid
positions, or simply that we could not detect cleavage
within the dynamic range of the assay.
Collectively, these results reveal how the HIV-1
PR has evolved dual specificity to accommodate
either the presence or absence of a P1′ proline. Such
adaptation is necessary due to the fact that the
proline alters the orientation of the P2 and P2′ side
chains. By having S2 and S2′ subsites with dual
recognition specificity, the PR is able to define two
distinct classes of substrate specificity.Discussion
We have used cleavage rates from over 150
distinct substrate sequences to explore the basis of
HIV-1 PR cleavage site specificity. Since the initial
separation of retroviral cleavage site sequences
into those with and without a P1′ proline [24], there
has been a question of whether substrate require-
ments would differ between the two families. Our
data revealed the existence of two different substrate
motifs, NΩ/PI and βΦ/ΦE, and that they are related
to each other in a quasi-palindromic fashion in which
important interactions with the N- and C-terminal
halves of the substrate are switched between them.
In βΦ/ΦE motif sites, a β-branched P2 residue
occupies a majority of the S2 subsite, interacting with
a region of hydrophobic amino acids while avoiding a
more polar region outlined byPR residues Asp29 and
Asp30. However, a P1′ proline alters the substrate
interaction with the S2 subsite [48], reorienting the P2
side chain to face away from the scissile bond and
into the hydrophilic region in the distal portion of the
S2 subsite. There appears to be an opposite effect on
the P2′ amino acid where the presence of a P1′
proline alters the positioning of the P2′ amino acid
side chain that favors interaction with the equivalent
hydrophobic region of the S2′ subsite, while the
absence of a P1′ proline favors polar interactions with
Asp29′ and Asp30′ in the distal portion of the S2′
subsite.
In generating our data, we engineered a system that
used a globular protein substrate under near physio-
logical conditions, and included an internal control
substrate to act as a reference point from which
we could reliably compare rates across reactions.
A number of prior studies have examined HIV-1 PR
substrate specificity [16,24,31,34], although the vast
majority of these made use of variably sized peptides
under high-salt and low-pH conditions [44,47–56],
neither of which represent conditions likely encoun-
tered by the enzyme during virion maturation [57].
These studies largely have general agreement in
substrate preference (i.e., rate of cleavage) with a
relative order of SP1/NC N MA/CA N CA/SP1 N
SP2/p6, although as noted earlier, SP2/p6 is cleaved
much more rapidly in the context of an intact Gag
substrate. However, while the order is largely
preserved, the reported relative rate of cleavage
between substrates varies widely in these studies
(Supplementary Fig. 3). Moreover, these studies
often mutagenized only a single target sequence
(most often MA/CA or CA/SP1). Certain conclusions
derived from these previous studies were found in
our current study, namely, the general flexibility in the
external P4, P3, P3′, and P4′ positions and the critical
role of P2 [46,49–51]. Other conclusions appear to be
incomplete due to the limited number of cleavage
sites examined. For example, multiple studies report-
ed glutamic acid to be the ideal P2′ residue [47,48,53];
in contrast, we found the specificity of the P2′ amino
acid to be context dependent. Not only was glutamic
acid suboptimal to β-branched amino acids in NΩ/PI
motif sites, but its selectivity inversely correlated with
the size of the P1′ residue in βΦ/ΦE motif sites. In this
regard, it has been reported that a P2′ glutamic acid
is the most active amino acid given an aliphatic P1′
amino acid such as norleucine [48].
The existence of two motifs raises the question of
why HIV-1 does not evolve to utilize one or the other.
We aligned approximately 1100 HIV-1 subtype B
Gag sequences to look for patterns of variability
(Supplemental Fig. 4) and found significant conser-
vation at amino acid positions where a replacement
could vastly improve the rate of cleavage in our
assay (e.g., P2 asparagine in SP2/p6; Fig. 5a).
Considering the prolines of NΩ/PI sites have known
functional roles outside of substrate recognition, this
high level of conservation in βΦ/ΦE sites may
similarly identify residues that take part in critical
non- or post-cleavage functions. Indeed, CA/SP1, a
βΦ/ΦE motif site, assumes an alpha-helical confor-
mation during assembly to stabilize the immature
capsid lattice [58–60], and mutagenesis of the site
disrupted formation of virus-like particles [61].
Conversely, the fact that the observed variability
that is present in cleavage site sequences would
not change the order (meaning the intrinsic rate
of cleavage) in which cleavage sites are cleaved
implies selection for specific cleavage rates to
temporally control certain processing events during
virion maturation. While there is general agreement
about the order of cleavage during maturation, the
extent to which the kinetics of the cleavage events
can be altered without affecting infectivity remains
unexplored.In this study, we have focused on the primary
sequence of the cleavage sites. While general
features of the rate of cleavage are reproduced
based on the primary sequence, it is clear that at
least for some sites there will be additional rate
determinants based on the context of an intact
Gag or Gag-Pro-Pol precursor. For example, despite
being a relatively poor substrate based on the
cleavage site sequence alone, the SP2/p6 site
is cleaved relatively efficiently in the context of a
wild-type Gag molecule suggesting additional local
determinants of cleavage [10,31]. In some cases,
the P5′ position of the SP2/p6 site can be mutated in
the context of selection for high level resistance
to a PR inhibitor (along with the P1′ site) [62,63],
suggesting a role for context beyond the substrate
binding cleft of the PR for at least some sites.
Finally, a review of cleavage sites for other
retroviruses can show if this pattern of use of the
P2 and P2′ amino acids is conserved. The presence
of a polar amino acid in P2 paired with an aliphatic
amino acid in P2′ at the cleavage site that releases
the N-terminal proline of CA appears to be relatively
conserved among lentiviruses but not beyond [24].
The more generic pattern at the CA cleavage site
for retroviruses is one where both the P2 and P2′
amino acids are hydrophobic, likely pointing to a
more uniformly hydrophobic S2/S2′ subsite for these
viral proteases.
Our work has provided fundamental insight into
the nature of the amino acid specificity for HIV-1
PR cleavage sites as defined by the presence or
absence of proline in P1′. The HIV-1 PR is an
example of how the retroviral proteases are able to
carry out the unique process of recognizing cleavage
sites with or without the presence of a P1′ proline.
This insight provides a strategy for systematically
changing the rate of cleavage of sites, which will
allow an analysis of the role of PR cleavage rate in
these sites in the process of assembly and as a
determinant of virion morphology and infectivity. In
addition, it is now possible to conceptualize inhibitor
designs that could engage both specificities of the
S2 and S2′ subsites. In such a design, both the
hydrophobic face and the hydrophilic face of the S2
and S2′ subsites would have appropriate interac-
tions with the inhibitor with interactions that are
involved in these two patterns of substrate recogni-
tion and thus likely difficult to evolve resistance.Materials and Methods
Constructs
For the internal control substrate, the genomic
sequence spanning the MA and CA domains was
amplified from the pBARK plasmid, which contains
the full gag and pro genes of the HIV-1 laboratory
strain NL4–3, and subcloned into the pET-30b vector.
The sequence was modified to include an N-terminal
6xHis tag, a tetracysteine motif (CCPGCC) in the
cyclophilin A binding loop (His87–Ala92) of CA,
and three glycine residues between the P5–P4 and
P4′–P5′ amino acids of the MA/CA cleavage site
separating the domains.
The GMCΔ substrate was similarly derived from
pBARK. However, in addition to the 6xHis tag,
the tetracysteine motif, and the glycine residues, a
glutathione S-transferase domain was added be-
tween the 6xHis tag and N-terminal end of MA, and
the CA region was terminated at position 278. These
changes enabled detection by size of four different
tetracysteine-containing proteins in a single reaction
(the two substrates and their CA-containing products).
All changes to the P4–P4′ region ofGMCΔweremade
via PCR-based site-directed mutagenesis. Primers
were obtained through Sigma-Aldrich.
Expression and purification of the HIV-1 PR and
globular HIV-1 PR substrates
Escherichia coli BL21 DE3 lysogens (Novagen)
were transformed with the various plasmid derivatives
encoding the substrates and grown in MagicMedia
(Invitrogen) for protein production. Cells were pelleted
and frozen at −80 °C. After thawing, lysis was
performed by sonication in TBS (pH 7.5), 1% Triton
X-100, and 2 mM beta-mercaptoethanol. Cellular
debris was collected by centrifugation, and the His-
tagged proteins were purified by affinity chromatogra-
phy using the Ni-NTA Superflow columns (Qiagen).
Purified proteins were concentrated using Vivaspin
Concentrators (GE Healthcare), with buffer exchange
into storage buffer [20 mM sodium acetate, 140 mM
sodium chloride, 2 mM beta-mercaptoethanol, 10%
glycerol (pH 6.5)]. The pH was confirmed to within
0.2 unitswith amicro-pHelectrode (ThermoScientific).
Purified HIV-1 PR was produced as described
previously [64,65]. Briefly, HIV-1 PR was expressed
from a pXC35 E. coli plasmid vector. The cell pellets
were lysed and the PR was extracted from inclusion
bodies with 100% glacial acetic acid. The PR was
separated from higher molecular weight proteins by
size-exclusion chromatography on a Sephadex G-75
column. The purified protein was refolded by rapid
dilution into a 10-fold volumeof 0.05 Msodiumacetate
buffer at pH 5.5, containing 10%glycerol, 5%ethylene
glycol, and 5 mM dithiothreitol (refolding buffer).
Two-substrate protease cleavage reactions
Two-substrate cleavage reactions were run in
proteolysis buffer [(50 mM sodium acetate, 50 mM
NaMES, 100 mM Tris, 2 mM beta-mercaptoethanol
(pH 6.5)]. Reactions were 150 μl in volume and pre-
incubated at 30 °C for 1 h before the addition of theenzyme to allow theLumioGreenReagent (Invitrogen)
to bind the CCPGCC motif in the CA region of each
protein. Both substrates were included at an initial
concentration of 1.2 μM. The HIV-1 PR was used at a
concentration of 150 nM in the two-substrate assays
where the substrates lack the glycine insertions and
400 nM when the glycines were present to make up
for the minor drop in processing rate. Aliquots were
collected at specific time points throughout the course
of the reaction and added directly to a tubewith SDS to
halt the reaction. The zero time point was removed
immediately prior to the addition of enzyme. Most
reactions were limited to 15 min, the time frame
required for the internal control to reach approximately
50% processing, although only data points generated
within the first 10% of processing were used to
generate relative rates. Sites exhibiting b10% cleav-
age after 15 min were retested in extended, 120-min
assays. If cleavage was still not observed after
120 min, the site was classified as not cleavable.
After the final timepointwas collected, reaction pHwas
confirmed as 6.5 using a micro-pH electrode (Thermo
Scientific). Substrates and products were separated
by SDS-PAGE using precast 16% Tris-Glycine gels
(Invitrogen). The fluorescently labeled proteins were
then imaged with a Typhoon 9000 (GE Healthcare/
Amersham Biosciences) and quantified by Image-
Quant TL (GEHealthcare) software. The initial reaction
rate for each substrate was determined using only the
data points collected where the reaction was ≤10%
complete or was estimated based on the first non-zero
data point collected. To determine the relative rate of
processing, the ratio of initial velocities was compared
using the internal control as the denominator, and the
value recorded. The relative rate for each mutant was
determined in at least two separate reactions. The
average variance in estimated rate between the two
reactions was 1.25-fold, with a range of 0 to 2-fold.
Overall, these values differed by over 3000-fold and
were log-transformed for ease of interpretation.Acknowledgments
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